MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
POSITION SUMMARY
This position supports key Scientific Affairs initiatives aligned with the strategic plan, focusing on diagnosis and education related to genetic causes of cholestasis, including adult PFIC and unexplained cholestasis. Additionally, this individual will serve as a genetics and disease expert for Smith-Lemli-Opitz syndrome (SLOS), bile acid synthesis disorders (BASDs), Zellweger spectrum disorders (ZSDs), and cerebrotendinous xanthomatosis (CTX), with a focus on patient diagnosis and treatment. This position is field-based requiring engagement with physicians, key opinions leaders in medicine and research, and patient advocacy leaders.
JOB FUNCTIONS/RESPONSIBILITIES
- Support disease state education and reinforce the importance of diagnostic testing and treatment in cholestatic liver disease, SLOS, BASDs, ZSDs, and CTX per request (e.g. grand rounds, executive presentations and KOL engagements)
- Educate physicians utilizing the company’s sponsored testing programs about best practices in interpretation of genetic results
- Expertly articulate relevant scientific and clinical information relative to the therapeutic area to HCPs and researchers
- Utilize scientific resources to deliver impactful presentations to varying audiences and in a variety of different settings including (but not limited to) advisory boards, patient advocacy groups, and payors
- Collaborating with external scientists and clinicians on projects related to the identification and treatment of diseases of interest
- Serving as point-of-contact for the sponsored-testing program in cholestasis and lead projects related to its optimization such as transition to WES as well as need for ongoing revisions and reflex testing
- Developing and executing strategy that facilitates the reclassification of variants of unknown significance in PFIC
- Supporting the development, analyses and dissemination of data from real-world registries and data repositories of genetic causes of cholestasis
- Facilitate and advance externally supported research concepts to Vice President of Scientific Affairs
- Contributing to the overall strategic plan and developing data generation and dissemination activities that support the plan
- Leading the development of scientific publications that support the overall (Livmarli) Brand Plan and Medical Strategic Plan that are directed towards the diagnosis and management of genetic cholestasis along with SLOS, BASDs, ZSDs and CTX
- Partnering with other functional teams to develop educational materials for different stakeholders (e.g., physicians, patients) that aid in the diagnosis and management of genetic cholestasis
- Educating appropriate internal teams on genetics of cholestasis
QUALIFICATIONS
Education/Experience:
- Masters degree in science such as MPH, MHS, or MS
- Minimum of 5 years of experience in medical affairs or clinical or scientific research, and publications
- Experience as genetics counselor and/or MSL preferred
- Ability to work collaboratively with external stakeholders and internal cross-functional team.
- Experience developing scientific publications, including liaising with authors and internal stakeholders, adhering to timelines, articulating key objectives of publications, and aligning scientific content to strategic imperatives
- Experience with clinical research including experience generating and analyzing data
- Proven ability to write and edit content for scientific abstracts, posters, presentations, digital enhancements, and manuscripts aligned with scientific narrative and objectives
Knowledge, Skills, and Abilities:
- Outstanding oral and written communication skills with the ability to communicate complex scientific concepts in a compelling and concise manner to various internal and external stakeholders
- Excellent interpersonal communication skills, strong personal integrity, and adept at networking.
- Ability to identify relevant literature to support scientific publications and strategy
- Skilled in the development and interpretation of data tables and visualizations to support scientific communication
- Able to analyze data with Excel or equivalent
- Well-versed using common tools in scientific publications including collaborative authoring through MS Word, PowerPoint and Excel
- Excellent collaboration skills to be able to work with other internal functions, external collaborators, authors/reviewers to obtain feedback and incorporate information into a final product
- Able to organize and prioritize tasks in order to maintain deadlines
- Travel up to 50%
#LI-REMOTE
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Job details
Mirum Pharmaceuticals
Pharmaceutical Manufacturing
About
Mirum Pharmaceuticals is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com.
Company Details
Jobr Assistant extension
Get the extension →